Product Description
Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in “Ph-like” B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents. (Sourced from: https://www.irbm.com/press-releases/irbm-to-disclose-strong-antitumor-efficacy-of-novel-preclinical-agents-against-aggressive-brain-tumors-and-acute-lymphoblastic-leukemia-at-aacr/)
Mechanisms of Action: CRLF2 Inhibitor,TLSP Inhibitor
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IRBM
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Acute Lymphoid Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|